Literature DB >> 12086092

Diagnosis and treatment of type 2 diabetes in three Belgian regions. Registration via a network of sentinel general practices.

J Wens1, V Van Casteren, E Vermeire, P Van Royen, L Pas, J Denekens.   

Abstract

BACKGROUND: The objective of this descriptive study is to investigate the incidence of type 2 diabetes in sentinel general practices in three regions in Belgium and to describe the patient characteristics and the start of the medical management after diagnosis.
METHODS: For two successive years all patients who were newly diagnosed with type 2 diabetes were registered. Two weeks after inclusion, the registering physician completed an extensive questionnaire. This questionnaire dealt with risk factors, biochemical parameters, existing complications and treatment.
RESULTS: According to this study, the yearly incidence of type 2 diabetes in Belgium is 231 per 100,000 inhabitants. Though the biochemical parameters (BMI, HbA1c, serum cholesterol and triglycerides) do not differ in the three regions of the country being investigated, there are considerable differences in the treatment prescribed for diabetes and its co-morbidity. In Flanders, treatment is usually started with sulphonylurea, in the Walloon provinces with biguanides. Hypolipaemic treatment is also started more frequently in the latter region. In Flanders, hypertension is registered in 51.4% of the newly diagnosed patients with diabetes, which is higher than in the other regions. However, no difference is noted between the different regions in the number of patients with diabetes who are treated for hypertension.
CONCLUSION: A network of sentinel physicians, taking part in voluntary registration, can be helpful in calculating the incidence of a health problem, in particular type 2 diabetes in general practice. The sentinel net can also serve as an instrument for describing patient characteristics and showing how physicians deal with health problems. The regional differences in medical approach that are described require further investigation, mainly with respect to their impact on the patients' outcome.

Entities:  

Mesh:

Year:  2001        PMID: 12086092     DOI: 10.1023/a:1015627912556

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  11 in total

1.  Diabetes care in Flanders.

Authors:  J Wens; P Van Royen; J Denekens; F Nobels
Journal:  Br J Gen Pract       Date:  2001-05       Impact factor: 5.386

2.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Tool for validation of the network of sentinel general practitioners in the Belgian health care system.

Authors:  M P Lobet; A Stroobant; R Mertens; V Van Casteren; D Walckiers; G Masuy-Stroobant; R Cornelis
Journal:  Int J Epidemiol       Date:  1987-12       Impact factor: 7.196

4.  Screening properties of questionnaires and laboratory tests for the detection of alcohol abuse or dependence in a general practice population.

Authors:  B Aertgeerts; F Buntinx; S Ansoms; J Fevery
Journal:  Br J Gen Pract       Date:  2001-03       Impact factor: 5.386

5.  Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset.

Authors:  T A Hillier; K L Pedula
Journal:  Diabetes Care       Date:  2001-09       Impact factor: 19.112

6.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

7.  [Study of non-insulin-dependent diabetes mellitus in primary care in the community of Madrid using the network of sentinel physicians].

Authors:  B Zorrilla Torras; J L Cantero Real; M Martínez Cortés
Journal:  Aten Primaria       Date:  1997-12       Impact factor: 1.137

8.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  4 in total

1.  Mail-order pharmacy use and adherence to diabetes-related medications.

Authors:  O Kenrik Duru; Julie A Schmittdiel; Wendy T Dyer; Melissa M Parker; Connie S Uratsu; James Chan; Andrew J Karter
Journal:  Am J Manag Care       Date:  2010-01       Impact factor: 2.229

2.  Incidence, prevalence and coronary heart disease risk level in known Type 2 diabetes: a sentinel practice network study in the Basque Country, Spain.

Authors:  J M Arteagoitia; M I Larrañaga; J L Rodriguez; I Fernandez; J A Piniés
Journal:  Diabetologia       Date:  2003-06-27       Impact factor: 10.122

3.  GPs' perspectives of type 2 diabetes patients' adherence to treatment: A qualitative analysis of barriers and solutions.

Authors:  Johan Wens; Etienne Vermeire; Paul Van Royen; Bernard Sabbe; Joke Denekens
Journal:  BMC Fam Pract       Date:  2005-05-12       Impact factor: 2.497

4.  Regional differences in antihyperglycemic medication are not explained by individual socioeconomic status, regional deprivation, and regional health care services. Observational results from the German DIAB-CORE consortium.

Authors:  Christina Bächle; Heiner Claessen; Werner Maier; Teresa Tamayo; Michaela Schunk; Ina-Maria Rückert-Eheberg; Rolf Holle; Christa Meisinger; Susanne Moebus; Karl-Heinz Jöckel; Sabine Schipf; Henry Völzke; Saskia Hartwig; Alexander Kluttig; Lars Kroll; Ute Linnenkamp; Andrea Icks
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.